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Multi Drug-Resistant TB and Extensive Drug-Resistant TB:
Regulating the Growing Crisis
Phillip DeFedele
phillip.defedele@gmail.com
The Bacterium
On August 30, 2012, The
Lancet published a troubling
study detailing the increasing
prevalence of drug resistant
strains of Myobacterium tuberculosis (“M. tuberculosis”), which
is the bacterium that causes tuberculosis (“TB”). M. tuberculosis, much like other bacteria, can
mutate in response to the drugs
used to eradicate them; thereby,
producing more resistant strains.

Russia, South Africa, South Korea, and Thailand with the purpose of examining the bacterium’s resistance to second-line
drugs.2 MDR-TB was confirmed
in 1278 (83.0%) of the 1540
baseline isolates collected, and
1199 (93.8%) of those 1278 had
a history of TB.3 Furthermore,
there was a high frequency of
resistance to second-line drugs in
MDR-TB at 43.7% and the 6.7%
risk of XDR-TB surpassed previous data provided by the World
Health Organization (“WHO”),
which showed a risk of only
5.4%.4 However, the prevalence
of XDR-TB in the study ranged
drastically from 0.8% to 15.2%
indicating an increasing concern,
especially in areas with high frequencies of XDR-TB.5
Regulating Disease

To be classified as Multi DrugResistant Tuberculosis (“MDRTB”) the bacterium must be resistant to at least rifampicin and
isoniazid; in contrast, Extensive
Drug-Resistant
Tuberculosis
(“XDR-TB”), essentially a more
resilient form of MDR-TB, requires the strain to be resistant to
the aforementioned drugs as well
any one of the fluoroquinolone
antibiotics and at least one second-line injectable antibiotic.1
The study was conducted from
January 1, 2005 to December 31,
2008 involving subjects from Estonia, Latvia, Peru, Philippines,

Fortunately, the WHO has
taken precautions to prevent the
spread of disease by adopting the
International Health Regulations
(“IHR”) on May 25, 2005, which
went into effect on June 15,
2007.6 The purpose of the IHR is
to “prevent, protect against, control and provide a public health
response to the international
spread of disease.”7 They do not
address particular diseases in order to maintain their adaptability
and applicability in the face of
continued disease evolution.8 The
IHR consists of sixty six articles,
which form the basis of the regulations, as well as nine annexes
and two appendices that supple-

ment and further explain the within
provisions.9 Of these sixty six articles, eight are specifically applicable
to the current issue of MDR-TB and
XDR-TB.
Article 5 Surveillance and
Article 6 Notification regard the
Member States’ obligation to detect
and report any events which may
constitute a public health emergency
as well as to “develop, strengthen
and maintain” the capacity to do
so.10 Article 12 Determination of a
public health emergency of international concern details the guidelines
used by the General-Director of the
WHO when determining an international public health emergency, and
Article 13 Public health response
requires the Member States to
“develop, strengthen and maintain…
the capacity to respond promptly and
effectively” to such international
emergencies.11
These articles are supplemented by Annex 1, which details
the core capacity requirements for
surveillance and response, and Annex 2, which assists Member States
in determining whether an event
may constitute an international public health emergency that should be
reported to the WHO.12 Article 17
Criteria for recommendations lists
the criteria the WHO will consider
when issuing, modifying or terminating any health recommendations,
while Article 18 provides potential
recommendations.13 General obligations are also set forth in Article 19
regarding point of entry, which is
also supplemented by Annex 1 and
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concerns both persons and cargo.14
Through these articles,
the WHO establishes the baseline
requirements its Member States
must follow in order to comply
with the goals of the IHR. However, Article 43 permits Member
States to implement their own
health measures as long as they
achieve an equal or greater level
of health protection than WHO
recommendations or are consistent with the IHR.15 The United States is one such member
state that has established its own
control laws and policies regarding TB.16 While the IHR are essential to the control and prevention of disease in general, the
WHO has initiated programs specifically tailored to address TB.
The most recent manifestation of the WHO’s efforts to
curb TB is The Stop TB Strategy
(“The Strategy”), which was implemented in 2006. This new
stratagem to combat and ultimately eliminate TB relies upon
the preexisting Directly Observed
Treatment,
Short-course
(“DOTS”) strategy and expands
its scope to confront additional
challenges in TB control.17 This
program was implemented due to
deficient progress towards the
goal of halving the prevalence
and mortality of TB by 2015 resulting from emerging obstacles
– i.e. MDR-TB and HIV.18 The
Strategy is based on six components: (1) Pursue high-quality

DOTS expansion and enhancement, (2) Address TB/HIV, MDRTB and other challenges, (3) Contribute to health system strengthening, (4) Engage all care providers,
(5) Empower people with TB, and
communities, and (6) Enable and
promote research.19
DOTS expansion and enhancement is the “cornerstone”
and foundation of the Strategy that
concerns political commitment
with increased and sustained financing, case detection through
quality-assured
bacteriology,
standardized treatment with supervision and patient support, an effective drug supply and management system, and a monitoring and
evaluation system and impact
measurement.20 The second component requires implementing collaborative TB/HIV activities, the
prevention and control of MDRTB, and addressing high-risk
groups such as prisoners and refugees.21 This component is the most
significant, next to the DOTS expansion and enhancement, because
it confronts the primary impediments to controlling and eliminating the disease. HIV fuels the TB
epidemic by increasing the rate of
recurrent TB, promoting the progression of latent and recent infections to active disease, and causing
worse treatment outcomes and
higher mortality.22 Therefore, the
Strategy urges collaborative activities to address joint infection and
reducing the burden of TB in HIV
patients and vice versa.23 Furthermore, MDR-TB is recognized as a

global threat to TB control due to
inadequate treatment, rise in drug
resistance caused by misuse of
second-line drugs, and the lack of
new drugs to treat MDR-TB.24
The Strategy requires management of MDR-TB through detection, utilizing adequate treatment
methods, a supply of reliable
drugs, and assessments determining the capacity of TB control
programs to manage MDR-TB.25
Finally, it is essential to
determine and address the needs
of groups with higher risks of
contracting and spreading the disease, such as prisoners, refugees,
displaced peoples, migratory
workers, the orphaned and homeless, and those with impaired immune systems.26 It is equally important to pay close attention to
special situations such as unexpected population movements due
to war, political unrest, and natural disasters.27 Even with this new
and improved strategy that recognizes the importance of detecting
and managing MDR-TB, the
WHO still found it necessary to
pass a resolution further addressing this issue.
At the Sixty-second World
Health Assembly, which took
place on May 22, 2009, a resolution was passed specifically addressing the prevention and control of MDR-TB and XDR-TB.28
This resolution, formally known
as WHA62.15, not only places
Continued on page 6
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‘Multi-Drug Resistant’
responsibilities upon all Member
States of the WHO, but also the
Director-General.
WHA62.15
strongly urges the Member
States to: (1) attain universal access to diagnosis and treatment
of MDR-TB and XDR-TB, (2)
enhance quality and coverage of
DOTS in order to reach a detection rate of 70% and successful
treatment rate of 85% to prevent
secondary MDR-TB, (3) use all
financing mechanisms to fill
funding gaps acknowledged in
the Strategy, and (4) increase
investment by countries and partners in the research and development of new diagnostics, medicines, and vaccines to prevent
and control TB, MDR-TB, and
XDR-TB.29 Furthermore, it requests the Director-General to:
(1) provide assistance to Member
States to develop and implement
response plans for prevention
and control of TB, MDR-TB,
and XDR-TB, (2) provide assistance to Member States to develop and implement strategies to
engage all health-care providers
in training for and increasing
prevention and control of TB,
MDR-TB, XDR-TB and TB/HIV
co-infection, (3) advise and support Member States to bring national drug regulatory standards
up to par with international
standards, (4) provide support to
Member States for upgrading
laboratory networks and facilitate evaluations of new and more
efficient diagnostic technology,

(5) help expand access to quality
assured first and second line
drugs, (6) explore and promote
incentive schemes for research
and development, (7) work with
countries to develop indicators
and support monitoring and evaluation of the implementation of
the measures in the resolution,
and (8) report through the ExecuIT IS CLEAR THAT THE WHO’S ACTIONS IN PREVENTING THE SPREAD
AND CONTROL OF TB HAVE THE
POTENTIAL TO PAVE THE ROAD TO
A WORLD FREE OF TB. HOWEVER,
BECAUSE THERE IS NOT ENOUGH
EVIDENCE SUFFICIENTLY DETAILING THE DISTRIBUTION OF MDRTB….THE ABILITY TO IMPLEMENT
THE WHO’S PROVISIONS IS GREATLY COMPROMISED.

tive Board to future assemblies on
overall progress.30 Like the IHR,
WHA62.15 is a legislative attempt to control and prevent the
spread of disease, but addresses a
specific disease. Additionally, it
places a greater burden upon the
Director-General to assist Member States, which certainly benefits poorer and less developed
countries. The IHR, the Strategy,
and WHA62.15 are the WHO’s
primary weapons in confronting
the issue of TB as a whole, including MDR-TB and XDR-TB,
but the ultimate question is
whether or not these are adequate
in the face of recent findings.

Application Today
Dr. Sven Hoffner of the
Swedish Institute for Communicable Disease Control finds the
prevalence of MDR-TB and XDR
-TB a great cause for concern.
Taking the aforementioned study
as well as other resources at his
disposal into account, Dr. Hoffner
finds that most recommendations
for MDR-TB control were developed for a prevalence of 5%, but
today’s prevalence may be as
much as ten times higher in certain locales.31 He also alleges that
despite all the research and studies done regarding MDR-TB there
is still a need for “more solid epidemiological information” in order to understand the development and transmission of the disease.32 Dr. Hoffner is hopeful that
the study published in The Lancet
will contribute to the identification of tools necessary to control
MDR-TB, but ultimately feels
that there is insufficient information revealing the true distribution and magnitude of XDR-TB.33
These contentions are further supported by facts presented by the
WHO which found that an estimated 37% of TB cases in the
world go undetected and untreated.34
It is clear that the WHO’s
actions in preventing the spread
and control of TB have the potential to pave the road to a world
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free of TB. However, because
there is not enough evidence sufficiently detailing the distribution of MDR-TB and its prevalence varies greatly from place to
place, the ability to implement
the WHO’s provisions is greatly
compromised. Additionally, given the turbulent times the world
now faces, people are fleeing
their home countries in exceptionally large numbers. Relocation of this sort can lead to the
transmission of diseases because
of the breakdown of social support and thus requires a careful
eye, as outlined in the Strategy.35
One such situation is the
migration of Africans to the Sicilian island of Lampedusa due
to the current political unrest in
many North African countries.
Unfortunately, in May 2012, an
inspection performed by the
WHO in conjunction with Italian
authorities, including the Minister of Health Renato Balduzzi,
found the health facilities and
services on the island inadequate, due to, among other
things, lack of access to water
and sanitation facilities, fire
damage from a riot in August
2011, and lack of housing facilities.36 Given the want of adequate care and inherently high
risk of TB spreading in displaced
populations, this situation is certainly precarious and may lead to
a substantial outbreak of TB and
disease in general. However, the
WHO and the Italian government

now recognize these issues and
have the opportunity to remedy
them through the guidance of
the IHR and TB prevention
measures.37 Although there is
still much to be discovered
about the true threat MDR-TB
and XDR-TB pose and their
prevalence, due to the WHO’s
actions in addressing TB and
disease control in general, the
world stands a fighting chance
in controlling and eventually
eradicating TB, especially as
more data becomes available.
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From School to the ‘Real World’: Transition Rights for Students
with Special Needs
which a school is held responsible
for linking graduating special
needs students to meaningful and
kristine.kodytek@gmail.com
useful post-school3 opportunities.
These transition services must be
Transitional service plans are more detailed and individualized
required by law to assist spe- in order to accomplish the goal of
cial needs students in integrat- integration into society.
ing into the community after
Under
the
IDEA,
graduating from high school.
“transition services” are “a coorKristine Kodytek

High school. College.
Law school. Career. The path to
becoming a lawyer requires these
essential transitions throughout
life: from school to the real
world. Though career planning
can be complicated and overwhelming for all students, a
heightened complexity exists for
students with disabilities. These
students are required by law to
transition from high school prepared for whichever future path
they choose—whether it be attending post-secondary schools
or joining the workforce. This
responsibility for preparation
falls largely on the shoulders of
the student’s school district.1 The
Individuals with Disabilities Education Act (IDEA)2 requires
that such transitional services be
mapped out within the student’s
Individualized Education Plan
(IEP) when the child is of high
school age. Although Congress
has explicitly determined that a
plan for transition services must
be present in a child’s IEP,
courts interpreting the law vary
on the legal accountability to

dinated set of activities” designed
to be results-oriented and focused
on improving a child’s academic
and functional achievement in
order to facilitate a successful
movement from school to postschool activities including, but
not limited to, post-secondary education, vocation education, integrated employment and independent living. Sufficient and successful transition services are based
on the child’s personal needs,
strengths, and interests and must
provide recommendations for: 1)
instruction, 2) related services, 3)
community experiences, 4) development of post-school employment and other adult living objectives, and 5) when appropriate,
the acquisition of daily life skills
and functional vocational evaluation.4
The IDEA’s statutory
goals shifted in 1990 from simply
providing educational access and
opportunities for students with
disabilities to actually improving
the quality of the education ultimately provided by requiring
planned transition services.5 Transition planning is recommended

to begin at the age of 14, or sooner, if the student’s IEP team, comprised of parents, educational faculty, school district staff, etc., feel
that an earlier start is more appropriate. By age 16, the student’s
IEP must include a detailed listing
of the specific transition services
needed, the agency responsible
for providing the service(s), and
needed or known linkages to
community agencies with or for
whom the student may work or
associate with post-high school.6
Just how far a school legally must
go in order to connect high school
students with disabilities to beneficial future opportunities is still
unclear.

Applicable case law demonstrates that the requirements
for acceptable transition plans
are unclear and open to interpretation by the states.
Interpretation
of
a
school’s efforts to connect students with post-education special
needs agencies in satisfaction of
IDEA requirements vary across
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jurisdictions. In some situations,
courts have held that simply informing the student and his or her
parents of the existence of posthigh school community agencies
was enough to satisfy the school’s
obligation.7 However, other courts
have held that Congress intended
for schools to go beyond just making students and their parents
aware of community agencies.
These courts articulate that Congress’ intent was for schools to actually establish relationships with
the outside organizations and even
include the agencies in an appropriate student’s IEP planning process.8 The importance of schools
collaborating with post-education
special needs agencies is immeasurable for a student’s future because these organizations will help
to make the rest of the lives of
these children more purposeful and
complete. Thus, “the establishment
of these community connections
should be viewed as an ongoing
process, not a one time venture.”9
There will always be students with
special needs filtering through the
public school system. The most
efficient practice would be to stay
in touch with these agencies so that
each new student who is entitled to
the protection of the IDEA does
not have to start from square one.
A student’s assertion of his
or her own future goals is a significant factor in the court’s view in
determining whether a school has
met the transition services requirement under the IDEA. For example, if a student suggests he or she

is interested in attending a community college, it is up to the
school to reorganize the student’s
IEP, via a meeting of the IEP
team, to include what preparations the student must make in
order to be accepted into community college, be familiar with and
utilize the special needs services
that can and will be provided to
him there and to succeed while
there.10
A student’s ability, or inability, to live independently after
graduating from high school is
another serious factor the court
considers when determining
whether the student had a proper
transition services plan implemented. A student who is provided with meaningful vocational
internships and socializing activities within the school system, and
who displays independence in the
school setting, still may be found
to have had an inadequate transition services plan. For example, if
a student is not educated on the
“basics” of independent-living
outside of high school, such as
normal self-hygiene and navigating various transportation
routes to get from his or her home
to an out-of-school agency, the
school will be deemed to have
failed the student in this aspect of
the transitions services requirement.11

New York is making efforts to
create better transition plans in
light of 2011 research that reported poor post-high school
activity for students with special needs.
In New York City, The
ARISE Coalition (ARISE) is
an organization comprised of
parents, educators, and advocates working to systemically
change New York City’s public schools for the benefit of all
students. ARISE is concerned
with students’ preparedness for
life after high school. In February 2011, ARISE compiled a
status brief focused on the need
to improve the educational process for students with disabilities transitioning to adulthood.
The brief revealed a 2009 statistic reported by the New York
City Department of Education
that less than seventeen percent
of students with disabilities in
New York State who graduate
high school are college and/or
career ready.12 In response to
this statistic, ARISE conducted
its own research by reviewing
over two hundred fifty New
York City student IEPs. The
major issue with most students’
IEPs was the overuse of stock
phrases within the transitions
services portion of the form. It
was common for IEPs that
were reviewed to state, for example, “Johnny will integrate
into the community with supports as needed.”
Continued on Page 10

PAGE 10

HEALTH LAW OUTLOOK

From School to ‘Real World’
This statement is completely
unbeneficial to the student in
question since it defines neither how he will integrate, nor
what support he requires to
prepare to integrate.13 The
high prevalence of unhelpful
generic statements such as
these illustrates how the use
of boilerplate language in
IEPs that merely expresses
integration is problematic,
and affirms that a student’s
IEP should be personalized
and created with an individual
student’s strengths, needs and
goals in mind.
No two students are
exactly alike and thus, no two
students should have identical
transition service plans. Transition plans must be detailed
and individualized, and such
vague language does not create an actionable process, in
writing, which can be followed by the student and the
IEP team throughout the
child’s time in school. With
such limited phrases being
inserted into IEPs, no goals
for the student are created.
Therefore, at the time of graduation, no progress can be
measured. Perhaps even more
troubling, the student may be
no better off when exiting
school than when he or she
had entered.
In order to alleviate the
state’s shortcomings with regards to its students with disabil-

ities, the New York State Education Department (NYSED) has
created Regional Special Education Technical Assistance Support Centers, one of which is located in New York City. These
centers are staffed with professionals specializing in transition
services, special education, bilingual services, positive behavior
interventions, etc.14 Additionally,
the NYSED has updated the
state’s IEP form to emphasize
THOUGH CAREER PLANNING CAN
BE COMPLICATED AND OVERWHELMING FOR ALL STUDENTS, A
HEIGHTENED COMPLEXITY EXISTS
FOR STUDENTS WITH DISABILITIES.
THESE STUDENTS ARE REQUIRED
BY LAW TO TRANSITION FROM
HIGH SCHOOL PREPARED FOR
WHICHEVER FUTURE PATH THEY
CHOOSE—WHETHER IT BE ATTENDING POST-SECONDARY
SCHOOLS OR JOINING THE WORKFORCE.

post-secondary school goals and
the means necessary to obtain
those goals. The NYSED has also
created streamlined electronic
IEPs with the incorporation of a
new Special Education Student
Information System (SESIS). The
SESIS online program is designed to preclude IEP teams
from glossing over the details of
the transition services process by
not allowing those facilitating the
meeting to proceed to the next
subject area without detailing the
student’s planned transition procedure. ARISE reported that be-

cause the program is still in its
infancy, it may not be possible to
measure its success for some
time.15 However, one could assume that such a program would
nudge IEP teams to err on the
side of including more actionable
goals for the student than not.
This program should lead to
more accountability for the planners, for example preventing or
lessening the use of stock
phrases about general integration
and creating for the student a
path to a better life postgraduation.
ARISE’s status brief urges IEP teams to be thoughtful,
collaborative, and understand
that “legal requirements are not
just red tape; they provide a
framework for the type of planning that needs to happen for
successful
transitions
from
16
school to adulthood.” The organization notes that although
NYSED does not require a student’s diploma goals to be identified at all during the planning of
transition services, it would be in
the best interest of special needs
students to have their diploma
goals outlined within their IEP.
Emphasizing diploma curriculum
helps ensure that the high school
provides the student with whatever required coursework might
be necessary for future educational or vocational programs.17
Finally, ARISE highlights the
importance of successfully linking students with the appropriate
outside agencies who can and
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will help support them in their post
-secondary endeavors.18 The organization
recommends
that
schools maintain a database of
community services geared toward
serving and working with those
living with disabilities.
Conclusion: Students with disabilities who possess detailed
transition service plans within
their IEPs will be more prepared to handle life after school.
Although the IDEA’s
standards for transition services
for students with disabilities seem
clear, interpretation of what is and
isn’t enough varies by jurisdiction.
As New York City’s ARISE Coalition urges, it is in the best interest
of special needs students for
schools to interpret the requirements provided by the IDEA as
the bare minimum. In order for
students with disabilities to truly
benefit from the educational opportunities the IDEA seeks to provide, they must have an appropriate place to go after they are
phased-out of the school system
by either accepting their diplomas
and/or reaching a certain age determined by the district. Students
with disabilities who contribute
and have access to proper, detailed
transition service processes within
their IEPs will be more prepared to
handle life after school. Welldeveloped transition plans give
students the ability to succeed in
higher education, vocational education and post-high school ca-

reers by providing a more useful curriculum. This curriculum must be designed with the student’s individual
needs, strengths, and interests in
mind, while they are still within the
protection of the public school system.
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Government Tokophobia: Unjustly Denying Pregnant Women
Access to Research
Joel Silver
joelbsilver@yahoo.com
Tokophobia, or the fear
of pregnancy, is a psychological
disorder predominately affecting
pregnant women.1 The disorder
involves a lack of confidence in
the mother and/or a concern of
harm to the fetus.2 As described
in the following paragraphs, the
disorder is not limited to pregnant women and—in selection
of research candidates—the government has promulgated a set
of regulations that reflects its
own form of tokophobia.3 In order to increase equality, autonomy and safety for pregnant
women, the government should
shed its tokophobia and rewrite
regulations to allow greater access to research for pregnant
women.
Research is defined as “a
systematic investigation designed to develop or contribute
to generalizable knowledge.”4
The justification for allowing
research on human subjects, particularly those who are at risk of
harm, is the corollary benefit in
the form of “generalizable
knowledge” obtained from research results.5 For example,
clinical trials for drug approval
may involve a risk of toxicity to
healthy individuals; however,
the studies are used to enhance
safety profiles of the drug.6 The
information gathered from re-

search provides guidance to a
prescribing physician to determine the right dosage and patient
to receive the drug.7 If no such
study is performed and the drug
is approved with latent toxicities
to an untested group of individuals, future patients in that group
are at a much greater risk of
harm.8

Under the current regulations, “generalizable knowledge”
is not an acceptable ground for
conducting research on pregnant
subjects.9 Instead, research involving pregnant subjects at risk
of harm is only permissible if
there is a direct benefit to the
mother or fetus.10 Accordingly,
participation in clinical trials involving pharmaceuticals or therapeutic devices is severely limited
for pregnant women because clinical trials generally involve risk
of harm without direct benefit to
the specific research subject.11
The Food and Drug Administration (FDA), which regulates clinical trials in the U.S., even goes so
far as to state that non-pregnant
women of child-bearing age
“must be counseled about the re-

liable use of contraception or abstinence from intercourse while
participating in the clinical trial.”12
Nevertheless, the same
drug that is too risky to test during research—where subjects are
carefully selected, monitored,
required to give informed consent and provided information on
the risks of the intervention—
will subsequently become available by prescription without sufficient knowledge or warning as to
its teratogenicity (toxicity to the
fetus).13 Accordingly, instead of
reducing the risk of harm to
pregnant women, the current regulatory regime just delays risk
until the drug is actually approved, when more people are
vulnerable and fewer are paying
attention.14
The Belmont Report,
which articulates the basic ethical principles for human subjects
in research, provides that injustice occurs when some benefit to
which a person is entitled is denied without good reason or
when some burden is imposed
unduly.15 The Department of Human Health and Services (HHS),
the government agency in the
United States that regulates human research, has, in contravention of the Belmont Report,
promulgated guidelines that unjustly deny pregnant women access to the benefits of research.16
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HHS states that in the selection of research subjects, review
boards “should be particularly
cognizant of the special problems
of research involving vulnerable
populations, such as children, prisoners, pregnant women, mentally
disabled persons, or economically
or educationally disadvantaged
persons.”17 Aside from pregnant
women, each of the groups cited in
the list of “vulnerable populations”
have diminished autonomy as a
result of physical confinement,
age, mental capacity, or desperation.18 Pregnant women do not
have diminished autonomy nor do
they lack decision-making capacity.19 Thus, they do not logically
belong to a “vulnerable population.” Such a designation is arbitrary, paternalistic and demeaning.
In reality, HHS and the underlying regulations are less concerned with pregnant women and
more with the vulnerability of fetuses; specifically, that pregnant
women cannot be trusted to make
decisions for their fetus. A woman
has the right to an abortion,20
which clearly puts the fetus at extreme risk of harm, yet she is denied a choice to enter into research
over concerns of harm to that same
fetus.21 By simply comparing
“risks” to the fetus, research is
clearly on much stronger footing
than abortion.
Pregnant women are permitted to engage in a number of
other activities that are proven to
be very dangerous to the develop-

ment of the fetus and, unlike the
investigatory nature of research,
hold out very little corresponding
benefit to the fetus (and arguably
even the mother). Some of those
activities include: smoking, drinking alcohol, eating sushi and even
participating in the Olympics.22
By permitting these activities, we
as society trust the woman to
make the best
decision for herself and the fetus. Thus, it is
unclear why in
the case of research, women are denied individual autonomy and the ability to
make their own fully informed
decisions. The only logical basis
is that research provides no corollary benefit worth protecting.
Research holds tremendous benefit in the form of
knowledge and the potential reduction of risk to generations of
future mothers. Without extensive
research, patients would be naïve
to the potential harm a particular
drug may cause. An alarming example of the risk of naivety is the
drug Thalidomide, which was approved for prescription to a select
group of people needing a sedative or tranquilizer.23 Thalidomide
was never licensed for general
use, nor was it approved for administration to pregnant women.24
Nonetheless, physicians touted
Thalidomide as a “wonder drug”
and prescribed it off label to pregnant mothers for alleviation of
morning sickness.25 The drug was
ultimately found to be a severe

teratogen and became responsible for as many as 20,000 horrific birth defects.26 Had the teratogenic effects of Thalidomide
been thoroughly evaluated prior
to approval, it likely would have
had many fewer victims.
While facially protective,
current provisions limiting access to research actually increase
the risk of harm to the fetus.
Denying pregnant women the
right to choose to enter research
is inequitable, paternalistic and
irresponsible. The ultimate decision as to whether the benefit
outweighs the risk should at least
partially lie with the mother and
not entirely with the government.
According to the court in
Planned Parenthood v. Casey,
“[t]he ability of women to participate equally in the economic
and social life of the Nation has
been facilitated by their ability to
control
their
reproductive
27
lives.” HHS and the legislature
should consider rewriting regulations to remove pregnant women
from the list of “vulnerable populations”
and
include
“generalizable knowledge” as a
justification for research to eradicate this inequality. In doing so,
the government can resolve its
tokophobia and put research in
line with existing federal law and
community standards, which already recognize that women
should be able to decide what is
in their own best interest and that
of the fetus.
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Criminalizing Prenatal Substance Abuse: Hurting Women and Their
Unborn Children
Sara Smith
Sara.elisabeth25@gmail.com
Introduction
Criminalizing drug use
during pregnancy is an attack on
women’s
bodily autonomy
framed as a protection of unborn
children. This framework reduces women to, “being little more
than incubators to unborn children.”1
This dehumanizing
stance has a negative effect on
the status of women in society
and violates women’s constitutional rights. Additionally, statutes and prosecutions targeted
toward prenatal substance abuse
do not accomplish the intended
goal of promoting fetal health.
As a result of this punitive legal
system, women, unborn children, and their families suffer.
This article will argue that a
public health framework, in contrast to a punitive legal system,
is a better and more functional
approach for addressing problems associated with prenatal
substance abuse.
A punitive legal approach endangers a woman’s
bodily autonomy. Bodily autonomy is the power of a woman to
make choices about her own
body, and specifically in the
context of prenatal substance
abuse, about her pregnancy and
treatment.2 When the legal system takes a punitive approach

towards women using drugs during pregnancy, it subordinates
women and takes away their bodily autonomy.3 This is not to say
that a woman’s bodily autonomy
is the only concern regarding prenatal drug use. Roe v. Wade established the states’ interest in
protecting the potential life of a
fetus; however, neither the woman’s right to privacy during pregnancy nor the states’ interest in
potential life is absolute.4

aims to balance the interests of
women’s autonomy and the
states’ interest in potential life
resulting in policies that are more
functional and just for women
and their families.9

Policies
criminalizing
drug use during pregnancy pit
fetal rights against women’s
rights and ultimately conclude
that fetal rights trump the rights
of women.5 Women using drugs
during pregnancy have been
charged with crimes ranging from
assault with a deadly weapon to
child endangerment and often
receive stricter sentences than
drug users who are not pregnant.6
This leads to the conclusion that
pregnancy is a dominant factor in
prosecutions, and it becomes
clear that this punitive approach
serves as another way for the
state to reduce a woman’s bodily
autonomy.7 As discussed below,
the punitive framework for drugaddicted pregnant women may
actually hurt the fetus it is supposed to protect because it can
result in fewer women seeking
pre-natal care or drug treatment
as well as children being separated from their mothers.8 In contrast, a public health approach

The Supreme Court established in a line of case law,
and affirmed in Roe v. Wade, that
the Constitution provides a general right to privacy.10 Further,
Roe v. Wade established the right
to privacy in the context of terminating pregnancy; so it follows
that this fundamental right to privacy must also apply to a woman’s choices during pregnancy.11
Within that right to privacy is the
fundamental right to procreate,
first addressed by the Supreme
Court in Skinner v. Oklahoma,
invalidating the state’s forced
sterilization of certain “habitual”
criminals.12 The right to procreate was expanded upon in Griswold v. Connecticut.13 As one
scholar noted that while Griswold, “ … specifically discussed
only protecting the marital relationship, its holding in fact creates a right to privacy concerning
intimate matters such as decisions about procreation.”14

What does the Constitution say
about bodily autonomy and
targeting certain groups of
pregnant women for prosecution?
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When statutes criminalizing drug use during pregnancy infringe upon the privacy and procreation rights of women, they create a basis for an Equal Protection
claim.15 The Equal Protection
Clause of the Fourteenth Amendment was first applied to give
equal protection of the law to racial minorities but has since been
extended to apply to members of
suspect classes, including women.16 In order to analyze an Equal
Protection claim for state laws
dealing with prenatal drug use, the
level of appropriate scrutiny to be
applied to the law needs to be determined. The Supreme Court has
most recently applied a heightened
form of intermediate scrutiny to
gender based discrimination meaning a state must demonstrate an
“exceedingly persuasive justification”17 of a government purpose
for a law facially discriminating on
the basis of gender.18 Laws targeting pregnant women are facially
discriminatory because they only
apply to females; so, the government would have to provide an
exceedingly persuasive justification for an important government
interest.19 One potential counter
argument for the government to
respond with would be that it is
difficult and impractical to prosecute men for fetal harm caused by
drug use; however, that is not sufficient to justify an important government interest.20
Prosecutions
targeting
pregnant drug users are usually

based in a child abuse or endangerment statute and not an actual
drug abuse charge, and “pregnant
women receive harsher sentences
than drug-addicted men or women
who are not pregnant.”21 While
statutes addressing prenatal substance abuse target women, there
are no statutes or cases targeting
fathers of unborn children who
have used drugs that potentially
harm their sperm.22 Consequently, even though the right to privacy applies equally to men and
women, it is being applied differently in the context of drug use
and procreation simply because
women naturally carry the fetus
that took a man and a woman to
create.23 Thus, women are treated
more harshly when they are pregnant while men are not similarly
impacted when they use drugs and
procreate giving rise to an Equal
Protection Clause claim on the
basis of gender discrimination.24
Additionally, an Equal
Protection claim could be established where it is demonstrated
that state law disproportionately
impacts African American women
and there was some discriminatory purpose behind the state law.25
All too often, the common factor
in prosecutions against pregnant
women for drug use and hospital
drug testing on pregnant women
is that the women chosen for testing are African American.26 This
is true despite that fact that evidence shows drug use by pregnant
women is similar across racial

lines, but, “black women are
more than ten times more likely
than white women to be reported
for using drugs while pregnant.”27
This disparate impact strongly
implies that African American
women are being specifically targeted; therefore, it suggests at
least some evidence of a discriminatory purpose behind these laws.
Prenatal substance abuse
laws can also be attacked as a
Constitutional violation of the
Due Process Clause. An important tenet of the Due Process
Clause is fair notice of the scope
of what is forbidden by the language of the laws.28 This not only protects the accused from the
court creating illegality retroactively, but also emphasizes the
importance of the legislative intent.29 When women are charged
under various child abuse and endangerment statutes, they are not
given fair notice because almost
none of the statutes used to
charge women using drugs during
pregnancy include harm against a
fetus; thus, such charges tend to
equate a fetus with a minor
child.30 For example, in State of
New Mexico v. Martinez, the defendant was charged under a felony child abuse statute after admitting to using cocaine during her
pregnancy.31 Because the child
abuse statute in question did not
include a fetus in the statutory
meaning of “human being,” the
Continued on page 16
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court concluded that convicting
the defendant under the statute,
“would violate Martinez’s constitutional due process rights, as
she did not have prior warning
and fair notice that her conduct
was criminal under the statute.”32

state-sanctioned racial profiling
and gender discrimination.

While the state has an
established interest in the potential life of a fetus, a fetus is not
legally equivalent to a child and
therefore is not afforded the
same rights and protections.33
When women are prosecuted
under various child abuse and
endangerment statutes as a result
of using drugs while pregnant,
the state is effectively giving
personhood status to the woman’s fetus, setting a dangerous
precedent for policing women’s
every action and choice during
pregnancy such as the kinds of
food she eats while pregnant,
and her particular birth plan.34
This disturbing possibility is already starting to become a reality in South Carolina following
Whitner v. State of South Carolina35 which upheld Whitner’s
child abuse conviction received
for using crack cocaine during
her pregnancy, despite the fact
that her child was born
healthy.36 This is especially
alarming considering that in at
least one major South Carolina
hospital, African American
pregnant women are much more
likely to be tested for drug use
than Caucasian pregnant women.37 This opens the door for

It is clear that the punitive
approach to prenatal substance
abuse is constitutionally problematic for women; however, there
are still concerns about how to
best address the problems resulting from drug use during pregnancy. It is acknowledged that
drug use during pregnancy can
have detrimental effects on the
unborn child. Nevertheless, how
these women are dealt with afterwards is still of vital concern and
importance. A public health approach rather than a punitive approach is more functional for
women and their unborn children.
A public health approach can be
defined as one, “that identifies
the population-based factors that
may influence health, rather than
focusing on an individual’s personal behavior.”38
A useful
framework for comparing the two
approaches is thinking about the
rationales for a punitive approach
and the responses provided by
supporters of a public health approach.39

How a public health approach
promotes fetal and maternal
health while protecting women’s Constitutional rights.

The first rationale given
under the current punitive system
is that prosecution of prenatal
substance abuse will deter pregnant women from using drugs

because of the consequences of
prosecution.40 However, it appears that levels of prenatal substance abuse are not decreasing
and may be in fact increasing.41
Moreover, it is also shown that
prosecutions actually have the
opposite effect, causing women
to forego prenatal care altogether,
resulting in an even riskier situation for women and their unborn
children.42 This is further supported by many organizations
including the American Academy
of Pediatrics and the March of
Dimes who agree that a punitive
approach has the effect of deterring women from seeking medical treatment during pregnancy,
depriving themselves and their
unborn children of vital prenatal
care.43
The next rationale for a
punitive system is based on retribution and the idea that pregnant
drug users deserve legal punishment because their actions are
wrong regardless of how the punishment affects their lives or the
lives of their unborn children.44
However, this rationale ignores
the disease aspect of drug addiction as well as the social and economic disparities that often correlate with illegal drug use.45 Furthermore, the retribution rationale
should be analyzed with suspicion because it invokes Equal
Protection and Due Process concerns.46 Additionally, the idea of
retribution makes less policy
sense considering the limited
number of drug treatment options
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for pregnant women, and evidence
that many drug treatment centers
turn away pregnant women in a
time when they need treatment the
most.47
The final rationale used to
justify the punitive system to drug
use during pregnancy is that it promotes fetal and maternal health by
facilitating medical intervention.48
Unfortunately, the opposite appears to be true. When women are
incarcerated during pregnancy because of drug use, they are sometimes forced to give birth shackled
or in unsanitary prison facilities,
resulting in dehumanizing and potentially dangerous situations.49

Public Health Approach as an
Alternative
A public health approach
can provide functional solutions to
the challenges faced by pregnant
drug users while avoiding the constitutional and policy concerns
raised by the punitive approach.
Some of the best public health solutions focus on the importance of
prevention and treatment, specifically educating women about the
dangers of drug use during pregnancy and providing feasible treatment options to pregnant women
struggling with addiction.50 In order to encourage pregnant drug
users to seek vital prenatal care
and addiction treatment, programs
that can provide healthcare without fear of punishment need to be

established and funded.51
A major barrier for many
women seeking drug treatment is
the lack of healthcare coverage
and an inability to pay for a treatment program.52 It follows that
access to universal healthcare
coverage including drug treatment
programs and prenatal care would
alleviate this barrier for many
women.53 One specific example
of a public health approach includes California’s policy of addressing drug use during pregnancy that places the issue in the
realm of child protective services
rather than criminal law.54 Combining access to affordable treatment and handling by child protective agencies is effective because it removes the threat of
criminal prosecution while giving
a greater opportunity for maternal
and fetal health.55
It is also important for
treatment approaches to take into
account the fact that many women
who need treatment also have other children for whom they are responsible. Consequently, treatment programs should be welcoming to families and cognizant
of the importance of keeping them
together.56 This promotes the ultimate goal of a healthy woman
giving birth to a healthy child.
Conclusion
Accepting the status quo
punitive approach to avoid difficult reform devalues the high

stakes of promoting healthy
women and children. Protecting
an unborn child from the negative effects of drugs use does not
have to compromise the mother’s bodily autonomy and Constitutional rights. Fetal and maternal rights should be protected
together in the interest of a
healthy family. The best way to
do this is to establish a public
health system that focuses on
preventing and treating prenatal
substance abuse.
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Everyone Wants a Piece of Me: The Evolution of Biospecimen Research and the Regulatory World’s Attempt to Keep Up
A. Isabel Heine
Agnes.heine@student.shu.edu
A biospecimen is a sample taken from the human body
that can come in many forms,
including tissue, blood, and
urine, and contains a vast
amount of cellular material.1
Biobanks are the repositories that house these specimens
for safe keeping.2 They usually
involve cryogenic capabilities
for preservation and are maintained by the organization conducting the research.3 In 2009,
Time Magazine named Biobanks as one of the “10 Ideas
Changing the World Right
Now”.4 Needless to say, biospecimen research has been on
the rise, and an investigation into whether the regulatory world
has been able to keep up with
this progress is essential.
The National Cancer Institute (NCI) is at the forefront
of the biobanking movement due
to the potential information that
can be harvested from specimens that is also relevant to the
field of oncology.5 It is one of
the keys to the movement towards personalized medicine .
Biospecimen analysis can and
has led to better diagnostic,
prognostic, and staging techniques and outcomes in cancer
medicine by allowing for the
evaluation of disease suscepti-

bility.6 Time magazine raised
concerns surrounding the collection and storage of biospecimens,
including maintaining the privacy
of the individuals whose genetic
material is stored for future use
and the appropriate informed
consent procedures for obtaining
these specimens. These issues
are especially pertinent with regards to modern cancer research.

ty, employer, life insurer,
school or university, or
health care clearinghouse”
and “related to the past,
present, or future physical
or mental health or condition of an individual; the
provision of health care to
an individual; or the past,
present, or future payment
for the provision of health
care to an individual.”8

BIOSPECIMEN RESEARCH IS
EVOLVING AT A PACE FAR FASTER THAN THE REGULATIONS
THAT GOVERN IT. IT IS QUITE
CLEAR THAT CLARIFICATION IS
NEEDED, ESPECIALLY CONSIDERING THAT MUCH OF WHAT APPEARS ESSENTIAL TO PATIENT
PROTECTION IS SIMPLY A RECOMMENDATION AT THIS POINT.

Biobanking poses interesting
challenges to compliance under
HIPAA. One is whether a patient can ensure the confidentiality of their PHI when a chunk of
tissue can include vast amounts
of an individual’s genetic information and HIPAA is not clear
as to whether this type of information is covered. An individual’s entitlement to know what
information is collected from
their biospecimen is further debatable.

The Intersection of HIPAA and
Biospecimen Research
The Health Insurance
Portability and Accountability
Act (HIPAA) governs not only an
individual’s right to privacy of
their individually identifiable
health information, but also their
right to access their protected
health information (PHI ).7 PHI
is defined as:
“any
information,
whether oral or recorded in
any form or medium” that
“is created or received by a
health care provider, health
plan, public health authori-

Biospecimens are not directly covered by the HIPAA
privacy rule. However, these
specimens are often accompanied by identifiable PHI and may
therefore be indirectly covered.9
The Department of Health and
Human Services (HHS) established The Secretary’s Committee on Human Research Protections (SACHRP) in 2001 to advise the Secretary of HHS on issues surrounding the protection
of human research subjects.10
These recommendations can then

VOLUME VI, ISSUE 1

PAGE 19

Continued...
be used by local practitioners using informed consent and research
practices related to biospecimens.
Their most recent release in July
of 2011 was specifically targeted
to researchers and institutional review boards (IRBs) involved in
biospecimen research and provides
some clarification on the privacy
concerns by addressing any relevant HIPAA issues that arise under several commonly encountered
clinical scenarios.11 The guidance
issued by SACHRP is not promulgated regulations, and it is unclear
exactly how many institutions are
aware of and follow their recommendations. One such recommendation includes the use of an honest-broker, which involves placing
a barrier between clinical and research activities by removing any
HIPAA-designated PHI and preventing reidentification.12 An honest-broker can take the form of a
person or system that replaces PHI
with a code and then releases only
the coded information to the research team.13 The recommendation states that this honest-broker
procedure may be used “if appropriate” but does not define what an
appropriate circumstance would
be.14 Nevertheless, it would seem
that this would be the best way to
protect a patient’s identity
throughout the biospecimen collection process because it includes
measures to prevent reidentification by anything or anyone other
than the honest-broker.15 Another
benefit of this system comes from
the fact that an honest-broker is

the only link between research
identifiers and clinical identifiers
and therefore reduces the opportunity for conflicts of interest to
arise between the research and
clinical teams.16
Another recommendation
involves the use of Certificates of
Confidentiality.
These certificates are issued by the National
Institutes of Health (NIH) to protect PHI and other information
collected during a research study
from being forcibly disclosed by
investigators during any sort of
legal proceeding.17 Again, the
recommendations fail to explicitly
state where such a certificate is
appropriate and simply state that
they “may not be appropriate for
all biospecimen resources.”18
These certificates are promising
in that they have the potential to
encourage individuals to participate in biospecimen research. As
such, they could become a mandatory part of biobanking so that
participants are assured of confidentiality.
Additionally, if the hospital or institution performing the
biospecimen collection is a
HIPAA covered entity, the disclosure of any PHI would require a
HIPAA authorization from the
patient.19 Any subsequent disclosures of material containing PHI
to various entities would require a
new HIPAA authorization by the
patient if that entity was not covered in the original authoriza-

tion.20 This establishes a tracking mechanism of interested parties that desire access to a particular individual’s biospecimen
and places the research participant in control of who has access
to their information. A conflict
arises when attempting to comply with both the HIPAA Privacy Rule that governs research
authorizations and the Federal
Common Rule for Protection of
Human
Research
Subjects,
which governs the informed consent process. According to the
Privacy Rule, a research authorization must “pertain only to a
specific research study, not to
nonspecific research or to future,
unspecified projects.”21 The Privacy Rule considers the creation
and maintenance of a biorepository as a “specific research activity [and] the subsequent use or
disclosure by a covered entity of
information from the database
for a specific research study will
require separate authorization.”22
On the other hand, the Common
Rule allows for future research
to be consented to as long as the
informed consent document sufficiently details the future research.23 Although it would appear from a legal perspective that
the appropriate approach in dealing with seemingly conflicting
rules is to observe and comply
with the stricter one, it is unclear
how a research team on a local
level decides to comply with two
Continued on page 20

PAGE 20

HEALTH LAW OUTLOOK

‘Everyone Wants a Piece of Me’
rules that govern their biospecimen research. An informed consent document usually goes hand
-in-hand with its corresponding
research authorization, which
may cause further confusion for
the local practitioner.
HIPAA regulations and
NCI recommendations encourage the stripping of PHI from
biospecimens and the prevention
of reidentification, so how then
might federal regulations comply with a patient’s right to access any health related information derived from these specimens? Unfortunately it is not
clear whether information derived from biospecimens would
be covered under HIPAA, but it
would appear that genetic results
would qualify as information
that is “related to the past, present, or future physical or mental
health or condition of an individual…”24 Most human subjects research in the United
States is governed by the Common Rule.25 The Common Rule
necessitates several basic requirements related to the informed consent process, such as
that the consent form must include any additional costs that a
research participant may incur
from participation in the research and any reasonably foreseeable risks to the research participant.26 None of the rule’s
requirements includes an obligation to return any data, including
genetic information, to a study
participant.27 These same in-

formed consent regulations include that the following should be
provided to a research participant: “A statement that significant new findings developed during the course of the research

which may relate to the subject’s
willingness to continue participation will be provided to the subject.”28 Because results from genetic analyses could affect a participant’s willingness to continue
in a research study, the significance of the generated information should undergo careful
consideration when drafting an
informed consent.29
Stepping away from the
regulatory aspects and considering the ethical aspects of an individual’s right to information unfortunately and surprisingly does
not provide clarification. The
National Bioethics Advisory

Board (NBAC) closely examined
the ethical issues surrounding
research with biological materials, but made no reference to a
participant’s absolute right to
access data from their participation in a research study.30 The
NBAC did recommend that the
disclosure of research results be
an exceptional event that occurs
only when the results could have
an impact on the subject’s health
and ameliorative measures are
available to cope with the clinical implications of these results.31 This guidance is based
on what the clinician and researcher deems an appropriate
circumstance for disclosure, rather than addressing what the
patient may deem a disclosure
event. Additionally, the NBAC
ceased to exist in 2001 and no
similar government groups or
committees have been established to address the bioethics of
biobanking.32
A Truly Informed Consent
In 2008, the Arizona
Court of Appeals reversed a
summary judgment dismissal of
a claim by the Havasupai Native
Americans against Arizona State
University for unconsented misuse of their blood specimens.33
The Havasupai had initially consented to research involving diabetes, a disease that was plaguing
the tribe, but later learned that
data derived from their blood
samples had been used in various
publications unrelated to their
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initial purpose, such as schizophrenia, inbreeding, and population migration.34 Particularly upsetting was the report on population migration that directly contradicted the tribe’s own belief of
their origin.35 A large settlement
in favor of the Havasupai was
reached. In a New York Times
article on the case, Dr. David
Karp, a University of Texas Southwestern Medical Center internist
who studies informed consent for
genetic research, asked, “The
question is, how far do you have to
go? Do you have to create some
massive database of people’s
wishes for their DNA specimens?”36 One might think so and
current regulations contemplate
the progress towards a truly informed process of consent in the
field of biospecimen research.
A patient’s tissue has the
potential to outlast the patient.
Techniques
for
biospecimen
preservation have improved as the
prevalence of biobanking has increased. Thus, future and secondary uses of biospecimens have increased as well. The NCI Best
Practices guidance document on
informed consent recommends
that a tiered structure of informed
consent be instituted when biospecimens are involved so that patients can consent to only particular uses and not others .37 For example, if this tiered consent structure had been used in the case of
the Havasupai tribe, the participants would have been presented

with a consent form that would
have included the potential uses
for their tissue. They would have
perhaps consented to the use of
their biospecimens in diabetes
research but not to any sort of research involving evolutionary or
migratory patterns. This concept
of future consent is complicated
by conflicting federal guidelines.
The Common Rule allows for future unspecified research, while
HIPAA, as mentioned earlier, requires that every entity have authorization to conduct research.38
It is not yet clear how these differences are being reconciled in the
clinical and research settings.
The NCI has taken on the
task of attempting to provide clarification to local IRBs and biospecimen researchers. In 2011,
the NCI’s Group Banking Committee drafted an Informed Consent Template which gives a patient the power to decide whether
their biospecimens may be stored
and used for future research.39
Notably, the informed consent
was also written in very simple
language, with a preferred eighth
grade reading level, which addresses any concerns that a patient
may not fully understand what
they are consenting to.40
Future Considerations
Increasingly
common
within the field of oncology is the
practice of collecting a biospecimen upon entry to a clinical trial.

The ethics of this mandatory biospecimen collection, that is when
eligibility for a trial is dependent
upon undergoing a biopsy, is
currently being investigated.
Clinical biopsies are common in
oncology and are needed for diagnostic purposes. In contrast,
research biopsies are biopsies
performed for research purposes
only and have no established direct benefit to the patient.41
Within the research biopsies
group, there are two common
categories: 1) research biopsies
used for correlative studies that
are often exploratory and rarely
predefined; and 2) research biopsies used for studying an integral
biomarker and the results will be
used to guide patient care
throughout the study and oftentimes to determine eligibility for
study entry.42 There are always
safety risks with invasive procedures, but at least there is direct
benefit to the patient that balances out this risk when clinical biopsies are used for diagnostic
purposes. The concern over research biopsies is that you are
exposing a patient to a safety
risk when there is no established
direct benefit to the patient.43
Given the lack of direct benefit,
a patient should be given a very
explicit option to consent to a
research biopsy. But what if this
biopsy is an entry criterion for a
clinical trial? Some researchers
Continued on page 22
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have suggested that conditioning
study participation in this way
may be a form of coercion.44
Clinical trials are often entered
into because they are the last
resort for a patient. The level of
choice for someone during a
Phase I clinical trial, for example, is often severely limited. If
a patient does not want to undergo this biopsy, they should not
be barred from perhaps the last
therapy option available to them.
A survey of cancer patients
showed that approximately one
third of clinical trial participants
would be hesitant to participate
in a study involving mandatory
research biopsies but a larger
percentage (50%) said it would
have no impact.45 Very little has
been written on this topic and it
is still unclear how local IRBs
are reviewing studies that include mandatory research biopsies. A higher level of scrutiny
is appropriate for such studies,
especially regarding the safety
concerns. For example, a skin
biopsy may not necessarily increase the safety concerns but a
much more invasive liver biopsy
should affect the safety profile
of a study and therefore may not
be as readily approved by an
IRB.
Biospecimen research is
evolving at a pace far faster than
the regulations that govern it. It
is quite clear that clarification is
needed, especially considering
that much of what appears es-

sential to patient protection is
simply a recommendation at this
point. Moreover, the regulations
that do exist often conflict with
one another, as evidenced by the
disconnect between the HIPAA
Privacy Rule and the Common
Rule governing clinical trials research. The case involving the
Havasupai tribe is promising in
that it demonstrates the attention
the courts are willing to focus on
potential abuses of biorepository
banking and damaging resulting
consequences of research with
insufficient regulation and oversight in this area.
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Complications of Globalization: FDA Cracks Down on Fraud in the
Pharmaceutical Industry
Clarissa Gomez
Clarissa.Gomez@student.shu.edu
On February 14, 2012, the
United States Food and Drug Administration (FDA) announced
that 19 US medical practices had
purchased counterfeit Avastin, a
commonly used cancer drug, from
a foreign supplier named Quality
Specialty Products.1 Also this
year, two separate instances have
been reported concerning the purchase of counterfeit Vicodin, a
pain relief medication, via the Internet. Abbott Laboratories subsequently issued a consumer alert to
help prevent the sale of the counterfeit drug through rogue websites.2 In a third instance, in September, China State Food and
Drug Administration and the US
FDA initiated a joint campaign,
which resulted in the shutdown of
18 Chinese-language web sites in
America selling counterfeit drugs,
in violation of US laws.3
These incidents are only a
sampling of what the FDA’s Office of Criminal Investigations
(OCI)4 tackles. OCI is charged
with the responsibility to keep
consumers safe and to ensure the
public’s health, a broad delegation
that encompasses a wide array of
duties. In so doing, the FDA must
balance all the interests at stake–
the need for safe, legitimate medication and health care services,
while at the same time such medi-

cation and services must be affordable and readily available for
everyone in the nation. In light of
the need for a balance and as the
examples above show, the FDA
faces a dilemma since the demand
for drugs is high and there has
been a rise in both fraudulent, unlicensed drug manufacturers and
sellers, and counterfeit drugs on
the market. These issues are in
part the results of the rise in globalization, which largely affects the
nature of the pharmaceutical industry.
Black Market Rings and Globalization
Black market pharmacy
rings continue to threaten the nation’s public health. While many
ring members have been arrested
for violating the Federal Food,
Drug,
and
Cosmetic
Act
5
(FDCA), a myriad of problems
persist, and for a variety of reasons. For one, many undocumented immigrants purchase and seek
treatment from these FDCA violators who offer reduced services
and/or medication, out of fear that
their status will be discovered and
they will be deported if they seek
treatment at legitimate, statelicensed clinics.6 Second, some
criminals falsely claim to have
medical backgrounds, and sell
prescription drugs or counterfeit
drugs, perhaps even administering
injections.7 Furthermore, some
sell prescription drugs that have

been approved in a foreign country but have not passed FDA inspection in the United States.8
The issues are numerous
and the degree of harm grave.
Drug standards and regulations
vary from country to country,
and the FDA is responsible only
for those marketed and sold in
the US. The FDA accomplishes
this task by imposing stringent
standards for drug approval and
manufacturing. Additionally, US
pharmacists and wholesalers
must be licensed or authorized in
the states where they operate.
This type of process has been
referred to as a closed distribution system.9 Clearly, this system
is disrupted when counterfeit
drugs enter the market and when
individuals hold themselves out
as being licensed when they are
not.
Globalization has contributed to the rise and persistence of counterfeit drugs, as the
pharmaceutical industry’s complex manufacturing, operations,
and supply sourcing is increasingly being shifted overseas.10
These are particularly challenging times, due in large part to
tremendous breakthroughs in
science and technology.11 Such
worldwide
explosion
of
knowledge and capabilities affects many fields of research,
innovation, and industry.12 Currently, almost forty percent of
Continued on page 24
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American drugs are imported.
Moreover, nearly 80 percent of
the active ingredients in the
drugs on the American market
come from overseas sources.13 It
has been acknowledged that,
“in addition to the growth in
volume of imports, there
has been a dramatic increase in the variety and
complexity of imported
products. As the variety and
complexity of imported
products has increased, the
supply chain involving a
web of numerous repackaging facilities and distributors has correspondingly
become more intricate and
mysterious. Like any chain,
the drug supply chain is only as strong as its weakest
link, and the proliferation of
additional handlers, suppliers and middlemen creates
new entry points through
which contaminated, adulterated and counterfeit
products can infiltrate the
drug supply.”14
With the rise of globalization
and the increasing complexity of
the drug market, it has become
easier for the very kind of criminal behavior described earlier to
increase and persist.
The FDA Criminal Unit and
Special Agents
The special agents of the
FDA are the team of criminal

investigators within OCI who protect the public health from “theft,
counterfeiting, fraud, tampering,
and false advertising as spelled
out in [the federal laws].”15 The
special agents are equipped with
specialized knowledge and training to investigate violations
throughout the nation. OCI investigates about 1,200 criminal cases
each year that result in arrests of
about 300 criminal suspects; over
$11 billion in fines and restitutions were made from 1993
through November 2010 due to
OCI’s efforts.16
Of course and as with any
other agency, OCI’s resources are
limited and not every suspected
case can be investigated. Because
of this, the FDA continues to develop risk models17 and management tools to identify drugs and
their ingredients that are the most
at risk of economically motivated
adulteration. The FDA allocates a
majority of its resources and efforts to monitor those identified.18
Commissioner of Food and Drugs
Margaret Hamburg explained,
“We combine risk-based approaches with sound scientific
evidence to protect the public
from adulterated drugs and take a
number of factors into account in
determining whether a particular
drug ingredient may be at risk for
adulteration.”19 The FDA also
acknowledge that, to a large extent, their “success or failure in
this effort will depend on the relationships we establish and maintain with our foreign partners.”20

Thus, to mitigate the effects of
globalization the FDA engages in
joint efforts with other countries.21 Additionally, the FDA
launches national campaigns to
warn consumers of the various
risks they run, such as when purchasing from online pharmacies,
or how to keep an eye out for
counterfeit drugs.22
Challenges
to
prosecuting
FDCA violators: Illegal Internet Pharmacies
Under the FDCA,23 each
importer and each imported drug
must comply with the extensive
verification process laid out in the
Act. However, there are several
challenges to ensuring and prosecuting those who are in violation.
The Internet poses a huge problem in prosecuting FDCA violators. Because drugs can be legitimately sold via online pharmacies, there has been a rise in
many scam websites purporting
to be licensed when they are, in
reality, sham websites. Illegal
online pharmacies prey on prescription drug abusers and the
most vulnerable members of society who must rely on a daily
medicine regimen.24 These individuals make up a large portion
of their consumers.25 The National Association of Boards of Pharmacy (NABP) created the Verified Internet Pharmacy Practice
Sites (VIPPS) accreditation program in 1999 in order to help
consumers find safe sources for
purchasing medicine online, and

VOLUME VI, ISSUE 1

PAGE 25

Continued…
to avoid purchasing medicine
through fake online pharmacies.26
For
example,
federal
search warrants
were filed and
investigations entered this past
summer for the
illegal importation of low-cost
foreign
drugs27
sold by a Minnesota pharmaceutical
wholesaler
called
U.S.
Drugs, who is suspected of operating as a shipping hub for an online
pharmacy based in Winnipeg with
connections to entities in Barbados.28 The NABP reports that there
are more than 9,000 “rogue sites”
on the Internet, which are out of
compliance with U.S. pharmacy
laws and standards. Undercover
buys have been taking place in order for these illegitimate sales to
be uncovered.29 This issue is multi
-faceted, and in order for it to be
adequately addressed, there is a
necessity for advocacy and for information to be actively relayed to
all
those
involved
and
“victimized”.
Current FDA Legislative Action
In July of this year, President Obama signed and approved
the Food and Drug Administration
Safety and Innovation Act
(FDASIA), also known as the
FDA Reform Act of 2012, under
which several amendments to the

FDCA were made. These amendments aim to address various issues such as the nation’s current
drug shortage and to implement
policies to improve and accelerate
access to treatments and drugs.30
The Act also enhances penalties
for counterfeiting drugs, and Section 717 directs the Attorney General to “give increased priority to
effects to investigate and prosecute offenses under the law that
involve counterfeit drugs.”31 The
FDASIA adds to the Extraterritorial Jurisdiction provision of 21
USC §331 that, “over any violation of this Act relating to any article regulated under the Act is
such article was intended for import into the US…”32 Such an extraterritorial federal jurisdiction
provision enables United States
law enforcement to hold accountable those who violate our safety
law.33 The legislature, for the first
time in history, provides FDA
with information about importers
and enables the FDA to control
imported pharmaceuticals and devices. It also allows FDA to detain or to destroy counterfeit or
adulterated drugs, prohibit the entry of imported drugs that have
been delayed or been denied inspection by the FDA, and will encourage parity in the inspections
of domestic and foreign drug establishments.34
Despite these efforts by
the federal government to address
the issues regarding counterfeit
drugs and illegal internet sales,

one major recent criticism is
that Congress hasn’t gotten
around to passing certain legislation needed in order for
“FDA’s plan to level the plant
inspection playing field by visiting foreign plants at least as
often as it does U.S. facilities
[to] get off the grounds [as
soon] as planned.”35 Surely,
the ability for the FDA to inspect foreign plants plays a
role in its ability to ensure that
there is no criminal activity
within the US pharmaceutical
industry. This is also reflective
of the role of globalization and
its effects on the pharmaceutical industry, mentioned earlier.
“With an explosion in global
API [active pharmaceutical
ingredient] and pharmaceutical
manufacturing, the FDA has
been hard-pressed to keep up
with inspections.”36 Lawmakers have been discussing legislation which would grant the
FDA ability to better regulate
and inspect foreign plants and
drugs processed therein, but
such provisions were ultimately left out of the legislation
that did pass-thus the issue
will have to wait until after the
November 6 elections.37 This
is a pressing issue, since the
agency currently lacks resources to conduct reviews
and inspect facilities. Therefore, millions of dosages of
drugs come in from overseas
without any inspection. A majority of pharmaceutical
Continued on page 26
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ingredients are made in foreign
factories, but the standards in
these other countries fall below
those mandated by the U.S.38
Another major criticism
discussed during the Congressional hearings on the FDASIA
prior to its passage relates back
to the globalized structure of the
pharmaceutical supply chain.39
So much of the pharmaceutical
supply chain relies on interstate
commerce, and so federal government must ensure that
properly licensed entities are
involved in the pharmaceutical
supply chain. One speaker pointed to the fact that “the way prescription drugs are moved from
the manufacturer to the consumer has changed over the past several years,”40 and “we cannot
realistically expect to have a
thorough and comprehensive
national supply chain track-andtrace system without providing
for a clear and accurate definition of third party logistics providers.”41 Our federal laws must
reflect this new reality.
The rise in and effects of
globalization has been a common thread throughout this article, and I have hinted at but have
not explicitly mentioned how
transparency may effectively
alleviate some of its negative
consequences.
However,
it
should be clear how the transparency is fundamental. Only if
the consumers are aware of safety risks and scams, will they be

able to make smart and responsible choices. Further, while there is
no factual evidence, it can be
speculated that perhaps the enhanced criminal penalties will deter potential violators from acting
illegally, finding that the risk of
prosecution outweighs the benefits from engaging in counterfeit
drug distribution. Improving
transparency of FDA regulation
was also one major goal of Congress when passing the FDASIA;
GLOBALIZATION HAS CONTRIBUTED
TO THE RISE AND PERSISTENCE OF
COUNTERFEIT DRUGS, AS THE
PHARMACEUTICAL INDUSTRY’S
COMPLEX MANUFACTURING, OPERATIONS, AND SUPPLY SOURCING IS
INCREASINGLY BEING SHIFTED
OVERSEAS.

it was stated during a Congressional hearing on this legislation
that the bill includes significant
accountability
and
reform
measures designed to hold the
FDA responsible for its performance, and the committee overseeing the FDA can ensure that
the FDA is adequately performing.42 “A significant improvement
was made to the FDA’s ability to
police an ever-growing global
drug supply chain to improve patient safety, and these provisions
will give the FDA critical tools it
needs to keep our medicine safer.”43
Though it is ultimately
among the FDA’s responsibilities
to ensure the public health and

consumer safety, the effects of
globalization such as the rise in
sale of fraudulent drugs brings
rise to the need for all involved to
step up efforts against illegal drug
sales,44 including consumers
themselves. The FDA will continue its public education campaigns, using several different
approaches including the FDA
web site, radio and print public
service announcements, brochures, newspaper articles, and
outreach by public affairs specialists,45 in order to reach the maximum amount of consumers and
increase consumer awareness of
risks.
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Medical Malpractice Apology Law: “Don’t Tell Me What
Happened, Tell Me That You’re Sorry”
Courtney Lyons
Courtney.j.lyons@gmail.com
Last month, Massachusetts
passed a new law allowing for
medical malpractice apology reform with a “Disclosure, Apology,
and Offer” approach, hoping to
change the way lawsuits evolve
between the legal and medical
communities.1 The basic premise
of medical malpractice apology
laws is that patients are less likely
to sue for extreme monetary damages, or at the very least, more
willing to come to a meaningful
settlement conference if their emotional damages have been addressed by those parties responsible for the suffering.2 While over
half of the states have already enacted various forms of apology
laws, this new effort by Massachusetts is the most extensive and ambitious of its kind making patient
safety a top priority.
The Massachusetts Disclosure, Apology, and Offer approach
is far-reaching in its goals and the
medical and legal communities are
currently working through a series
of pilot programs to find out which
measures work most effectively.3
The goal of the law is to create a
proactive system that allows doctors to be frank and open with patients instead of being told by insurance companies that the medical staff is not allowed to contact
the patients. Under the law, doc-

tors are allowed to admit responsibility for patient injuries and
offer apologetic statements that
cannot be used as an automatic
admission of guilt in a court of
law. In the end, the goal is not to
avoid medical payments to suffering patients, but to make the process less adversarial, rendering
the court a last resort for conflict
resolution.4 Massachusetts legislators hope to tackle complex issues
surrounding patient relationships,
the measures needed to encourage
doctor disclosure, the tort system,
and how costs may be reduced
overall.5 With enactment of the
Patient Protection and Affordable
Care Act and its goals of cost containment in the national medical
system, the conversation now
turns to how unnecessary costs
can be avoided.6 In turn, states are
looking to reduce costs in every
possible arena, including litigation. Apology laws and similar
legislative efforts are a creative
way to bridge patient needs with
those of the medical community
in a mutually beneficial arrangement while at the same time, navigating the wake of adverse medical experiences.
Apology laws work to
open the lines of communication
that a functional doctor-patient
relationship requires. The Massachusetts law in particular creates a
six month “cooling off” period
between patients and medical professionals. This period allows

both sides to come to a better
understanding of what should
have happened during the medical treatment, what did happen,
whether positive or negative results, and how to proceed after
the fact.7 If a patient is angry
about a hospital stay or the results after a surgery, these concerns need to be addressed by
the responsible medical professional and in a timely fashion.
During this cooling off period,
the parties are required to come
to the negotiation table to exchange information about the
episode and doctors are allowed
the opportunity to safely offer
empathetic apologies without the
threat of admissibility in court.8
Legislators are hopeful this can
aid the state in moving toward a
more efficient process of handling medical malpractice cases.
There are several possible advantages to implementing
apology laws such as those being
reviewed and instituted by the
Massachusetts legislature. Instead of being stalled in courthouse discovery and trial schedules, cases can more rapidly
move toward meaningful negotiation because both parties have
committed to the mutual goal of
resolving the conflict, rather than
continuing the lawsuit for purposes of anger or revenge.9 Advanced apology laws create a
Continued on page 28

PAGE 28

HEALTH LAW OUTLOOK

‘Medical Malpractice Apology Law’
healthy mix of streamlined dispute resolution for both monetary and emotional suffering. In
this type of negotiation setting,
extra medical payments could be
offered by the physician to mitigate damages and patient relationships could be more effectively mended after these adverse medical experiences.10 In
moving toward this process, we
have to get away from a place
where the legal relationship with
the medical community dances
on the edge of mistrust because
of rising medical costs and quality of care issues.
Disputes are not static,
rather some scholars argue that
arguments and disagreements
are a social construct requiring
two actors, reacting to and advancing the situation.11 For two
parties to constructively work
through a disagreement and
reach a point of negotiation,
both must “perceive, interpret,
and understand the context of
the negotiation, the other parties,
and themselves.”12 Patients who
feel wronged by their doctors are
less likely to retain feelings of
anger and mistrust if a meaningful agreement is reached, ideally
one where a patient’s emotional
anger and financial injury have
both been redressed. Research
has shown that participants who
made a favorable evaluation of
an apology, that is, believed the
apology and its information
were adequate, were more likely
to agree to settle a case than they

were to reject an offer.13 In order
to get to an ideal point, apologies
cannot be simplistic statements of
sympathy or dry explanations of
the facts.14 It takes more than a
simple conversation to repair the
relationship between a doctor and
a patient who feels something has
gone wrong. We have to craft
medical malpractice apology law
to encourage the right kind of
apologies. Massachusetts takes
one step closer to this ideal in its
creation use of the Disclosure,
Apology, and Offer law.
When patients feel that
something has gone wrong, or
that a doctor has not treated them
the way they wanted, quick and
effective action is needed. While
it is unfair to say that every bad
result in medicine equates to a
particular doctor at fault, most
patients still aspire for open communication and assistance in
problem resolution.15 Honesty hits
at an important part of the medical malpractice process if patients
feel that facts were distorted or
that the doctors were not being
forthcoming. Doctors have so
long feared the unpredictability of
the medical malpractice industry
and the consequences of their patient interactions in a court of law
that the culture of practicing protectionist medicine has developed
without the opportunity for us to
stop, reflect, and correct it.16 An
apology works to chip away at the
raw anger the patient feels about
what has happened. Furthermore,
mere expressions of sympathy do

not achieve the same results as a
full acceptance of responsibility
and an expression of willingness
to work together to rectify the situation.17 In offering up full and
complete apologies rather than
statements of sympathy which
only get halfway to understanding, doctors bring themselves
down to the laymen’s level where
they can reach the level of humans who share the same goals.
In the end, we can hope to avert
“unwarranted malpractice claims
filed in anger instead of true
wrongdoing.”18 In the end, the
medical malpractice apology laws
are efforts to give angry patients
by giving them a sense of closure,
as well as reduce the amount of
extra punitive damages.
A harsh example of apologies gone wrong, outrage was
recently re-sparked in the case of
Thalidomide manufacturer Grünenthal when they issued an apology on August 31, 2012 expressing remorse for the negligent sale
of the dangerous drug in the
1950s.19 The drug, used by pregnant women to relieve morning
sickness, caused thousands of babies to be born with shortened or
missing limbs. The drug was
pulled from the market in 1961,
but no formal apology had ever
issued from the company.20 The
recently offered apology came so
long after the initial injuries,
many decades after thousands of
families were ignored in their suffering, that Grünenthal’s CEO
Harald Stock had to preface his
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statement with an apology for not
apologizing.21 As a result, the
goodwill effect that an apologizer
hopes the apology will have is
misplaced because the victims instead become focused on the neglect they previously faced.22
While it would have been inappropriate for the company to never
offer a statement of remorse for
the mistakes it made, one must
question the severe delay of this
particular Thalidomide apology.
Effective apologies provide remediation to the victims, opening up
a line of communication that assures the public that nothing as
horrific will happen in the future.23
If Grünenthal had apologized earlier, perhaps its victims would
have been quicker to forgive and
move on with closure in their
lives. Instead, the tragedy leaves
one with even worse tainted memories.

As an analogy for the city
dweller, the effect of proper apologies and the laws that allow for
them explain why commuters were
so pleased last November when
the NYC subway finally changed
their “This train is late” message.24
Previously, when someone was
delayed to work or school, the tinny, mechanical voice overhead
acknowledged that the train was
moving slow, but also added in a
reminder to, “Please be patient.”

Now we commute in a world
where the NYC subway not only
recognizes the inconvenience
caused but also adds in a remorseful “We apologize for the delay.”25 People want to be told that
the wrongdoers are sorry and that
they are doing everything possible
to fix it. The sting of conflict
comes most painfully when an
apology feels insufficient, insincere, or is offered far too late to
do any reparations. People do not
want the MTA telling them to be
patient. Similarly, we do not want
our doctors to tell us that something went wrong; there will be an
innate sense that something went
wrong when a medical bill has
extended far beyond the expected
cost, or an anticipated recovery
time period is botched by further
complication. Instead, we want
doctors to stop, accept responsibility for whatever part they may
have played in the error, and then
express remorse and empathy for
what is happening. Perhaps this is
what our nation’s doctors want as
well - to be able to relate to patients as real people without the
constant threat of lawsuit always
lurking behind them.
In the end, the new law in
Massachusetts and other efforts
across the country take great steps
toward opening up the conversation between aggrieved patients
and doctors nervous about the legal consequences of honesty. The
cloud of litigation looms over all
parties, but if the legal community

is able to work with both doctor
and patient, perhaps everyone
will be able to be more honest
with themselves about what
needs to be achieved. Patients
have a need to feel like people
after they have adverse medical
experiences and they want their
doctors to treat them like peers,
perhaps paying necessary bills
incurred out of the controversy.
Doctors have a need for the leeway to make healthcare decisions without fear that a lawsuit
will necessarily result and if
something adverse occurs, doctors need to be able to apologize
on a basic human level without it
being an automatic admission of
fault. Eventually, everybody’s
needs come down to emotional
human interaction. This is what
separates the bad apologies from
the good apologies, and this is
where we need medical malpractice laws to head.
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Gaps in Affordability: A Vision of Medical Bankruptcy through
Health Care Reform
Marco Ferreira
Marco.ferreira@student.shu.edu
Introduction
On March 23, 2010, President
Barack Obama signed into law
the Patient Protection and Affordable Care Act (hereinafter
“PPACA”).1 Congress intended
the PPACA to reduce the cost of
health care to the consumer and
to make health insurance affordable to all Americans.2 Prior to
the PPACA, fifty million individuals under age sixty five
were uninsured.3 Most of these
uninsured were part of a family
with at least one full-time worker.4 Often the reason for being
uninsured laid not with availability, but with affordability.
This Article purports to
conduct a simple analysis of the
actual affordability of health
care under the Patient Protection
and Affordable Health Care Act.
There is an unfortunate gap between the income level where
many of the new cost reducing
measures end and higher income
levels where households do not
feel the cost as sharply. Those in
this gap who experience significant medical costs beyond their
premiums risk medical bankruptcy due to extensive and expensive out-of-pocket costs.

What makes health care affordable
Any determination of what
constitutes affordable health care
will, at least to some extent, be
arbitrary
because
individual
households must determine what
level of coverage they believe
best suits their needs. For example, the PPACA health plans in
insurance exchanges fall under
several categories, each of which
carries its own premium price
based on actuarial statistics.5 Additionally, households have a variety of health needs with varying
costs. Combining these two realities results in a spectrum of actual
household expenditure on health.
There are, however, potential objective metrics of affordable care. The cost sharing subsidies and premium tax credits
available to those between 300%
and 400% of the federal poverty
level set the maximum percentage
of household income that a health
policy will cost at 9.5%.6 Ostensibly, this means that the federal
government believes that a policy
costing more than 9.5% of one’s
income becomes unaffordable.
However, ten percent may be a
better number to use as a baseline.
It is slightly higher than the 9.5%
and much evidence supports ten
percent of household income as
the line above which health care
becomes unaffordable.7 The same
research indicates that to fully understand and determine the af-

fordability of health insurance
and health care one must take a
holistic approach and take into
account all other necessary expenses.
One of the main approaches to defining affordability8 considers other (non-health related)
necessary budgetary requirements
on families.9 Necessary budgetary
requirements include childcare,
food, housing, taxes and transportation.10 Karen Davenport proposes two approaches to affordability.11 The first considers household budgets, measuring the dollar amount each household spends
on necessities and then treating
health care expenditures as an
extra expense.12 This approach
considers any remaining money
after the purchase of necessities
in the household budget to be
available for the purchase of
health care.13 Her second approach considers the share of income Americans can actually
spend on health care, measuring
premiums and out-of-pocket expenses as a share of income.14
Ms. Davenport postulates that
health insurance is unaffordable if
over ten percent of income must
be spent.15 Her approach is very
similar to the method employed
here: a determination of affordability using both objective and
subjective metrics.
The type of healthcare
plan analyzed in order to deter-
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mine the affordability of the
PPACA will be one obtained on an
insurance
exchange
created
16
through the Act. The analysis
will be narrowed by concentrating
on households in extremely expensive medical situations. These
families tend to be most at risk and
are the people the law should work
hardest to protect. In the most severe cases, the end result of serious medical costs can be bankruptcy.17 Since 2000, an estimated five
million families have filed for
bankruptcy in the aftermath of serious medical problems.18 The
families filing for bankruptcy do
not necessarily belong to lower
income brackets but indeed fall
under an array of income levels.19
This problem should be one that
the PPACA helps to alleviate (if
not eliminate) by allowing families, at any income level, the ability to deal with serious medical
problems affordably.20
Does the Affordable Health Care
Act actually make health care
affordable?
The first step in the analysis will be to find, generally, at
what income level health care
costs for the most expensive consumers become unaffordable. In
order to hone in on the specific
case where this may occur, it is
helpful to illustrate several scenarios generally and go in depth regarding the scenario of interest.
Health insurance premiums are
calculated in 2014 dollars and assuming an average insurance price

market.21 Premium calculations
are consistent with estimates of
premiums under the PPACA prepared by the Congressional Budget Office.22 However, it is important to note that all values are
estimates and subject to change.
Affordable care begins
with an analysis at the bottom level of household income, those
making less than 133% of the
poverty level. So long as the individual’s income does not exceed
133% of the federal poverty level
that individual may be covered
through Medicaid.23 The details of
Medicaid exceed the scope of this
article.
However,
coverage
through Medicaid may be acquired for very low, if not effectively zero cost.24 The efficacy of
Medicaid lies beyond the focus of
this article, and therefore it may
be assumed that households
whose income falls below 133%
of the federal poverty level may
obtain affordable health coverage.
The next scenario involves
a single forty-year-old adult making 134% of the federal poverty
level. Such an individual would
have $15,417 dollars in annual
income.25 This person’s unsubsidized health insurance premium
costs $4,500 dollars.26 However,
the maximum percent of income
the person must pay if eligible for
a subsidy is 3.06%.27 Therefore,
the insured would only actually
pay $472 dollars in premium, receiving a $4,028 dollar tax cred-

it.28 Additionally, the maximum
out of pocket (hereinafter
“OOP”) costs will be $2,083 dollars (which is equivalent to twothirds of maximum OOP cost for
any health insurance consumer).29 In the worst-case scenario,
assuming the most catastrophic
medical costs, this person will
have to pay $2,555 dollars in the
year for medical expenses. Although the premium only costs
this individual 3.06% of his annual income, should this person
require a lot of health care, and
incur the maximum cost, his or
her health care costs balloon to
16.6% of annual income.30 Such
cost at high levels of medical
expense demonstrates the risk of
medical bankruptcy, especially if
these costs are maintained for
several years.31
For a family of four making 134% of the federal poverty
level, household income increases to $31,389 dollars.32 In this
situation the pattern previously
demonstrated continues. The
premium price, through the
PPACA’s subsidy provisions,
may be completely reasonable at
3.06% of annual income.33 However, should the family experience serious medical issues and
be forced to pay the maximum
amount of costs under the
PPACA rubric this family’s
health care costs balloon to
16.3% of annual income.34
Continued on page 32
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A single 40-year-old adult when
making 250% of the federal
poverty level has an annual income of $28,763 dollars.35 Confronted with the most expensive
possible medical year, the total
medical costs of this individual
equal $5,440 dollars under
PPACA.36 In such a situation,
18.9% of the individual’s income must be spent on health
care. This increase can be largely contributed to the lesser OOP
cost protection.37
Like in the previous scenarios illustrating costs at 134%
of the federal poverty level, the
family of four’s relative health
cost, when making 250% of the
federal poverty level, comes to
similar values as the single adult
at 250% of the federal poverty
level. Assuming the worst medical financial situation, this family’s health expenses cap at
$10,964.38 Should the family
incur these maximum costs,
health care will constitute 18.7%
of their annual income.39
A single 40-year-old
adult making 403% over the federal poverty level makes
$46,466 dollars of income.40 In
the worst-case scenario, the individual will be responsible for
$10,750 dollars.41 Therefore,
should this person require the
most expensive health care
needs it will cost 23.1% of annual income.42
A family of four making

403% of the federal poverty level
makes $94,402 dollars of income.43 Should this family incur
the most expensive medical circumstances, this family will pay
$24,630 dollars.44 Should the
family be required to pay this
maximum amount due to expensive medical care, twenty six percent of their annual income will
go towards medical expenses.45
Medical costs will, of
course, be most expensive at incomes just over the end of
PPACA subsidization.46 As income increases, the percentage of
income spent on health care decreases. At some point health
costs revert back to subsidized
levels. For a family of four making 515% over the federal poverty
level, their income reaches
$120,638 dollars.47 Their health
insurance premium will be
$12,130 dollars, and they are not
eligible for any subsidies and so
will pay the full amount.48 This
premium price constitutes 10.05%
of the family’s income. The maximum OOP costs the family will
be responsible for is $12,500.49
Assuming the family must cover
the maximum amount, they will
incur $24,630 of medical expenses, which constitutes 20.4% of
their annual income.
A. The Gap in Affordability
These scenarios illustrate
two of the gaps in affordable
health coverage. For a single
adult, the PPACA seems to cover

all incomes (assuming the insured
remains healthy). The single adult
making just over where the
PPACA subsidies stop kicking in
only has their premium costs increase by a marginal 0.21%.50
The first gap in affordable coverage lies under middle class families with income levels between
approximately
$94,400
and
$120,600 dollars. When families
breach the barrier of federal subsidies, the baseline percent income spent on health coverage
jumps to over 12.85%.51 However, once a family’s income increases to around 515% of the
federal poverty level the premium
only costs 10.05%. As discussed
above, ten percent appears to be a
reasonable cost for a health insurance premium.52 So it would
seem then that, objectively, the
PPACA does not cover a significant amount of households within
the middle class of income level
and therefore leaves this group to
pay an unreasonably high premium price in relation to their income.53 The law, despite trying to
treat everybody equally54, continues in practice to maintain, albeit
unintentionally, a certain discrimination in terms of affordability.
Another dichotomy also
presents a troubling and serious
problem, illustrating the second
gap in affordable health coverage.
The difference between a premium costing ten or thirteen percent
of a household’s income, while
not achieving the PPACA goal of
affordable health coverage for all,
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likely does not pose too serious a
financial risk.55 However, the evidence presented suggests that the
PPACA envisions a system of affordable care for the healthy, while
condoning medical bankruptcy for
the seriously and chronically ill.
The family making 134% of the
poverty level must only pay 3.06%
of their annual income on the insurance premium.56 However, confronted with an extremely expensive medical situation, even with
the most protection in place, the
PPACA forces the insured to contribute 16.3% of their annual income to health expenses.57 This
portends the second gap where the
healthy may obtain affordable
health insurance while the chronically sick must still endure extremely high costs. For a family of
four making 134% of the poverty
level, this means that they must
pay $5,127 dollars from their income of $31,389 dollars, leaving
$26,262 dollars of income for the
year.
Out of this remaining
$26,262 dollars the average family
then must spend in necessities
about $27,950 dollars (in food,
housing, apparel, transportation,
and education).58 Although this is
a rough estimate, large health costs
clearly result in at least no savings
without taking into account any
amenities. At worst, a family with
the maximum health costs allowed
by the PPACA actually incurs debt
every year by simply purchasing
the necessities of life.

B. The PPACA continues to allow medical bankruptcy
When the PPACA ceases
to provide price protections, the
situation becomes much more dire
for the insured on the wrong side
of the line. For a family of four
making 403% of the federal poverty level facing the most expensive health coverage costs allowable by the PPACA, twenty-six
percent or $24,630 dollars will be
spent.59 From an after tax income
of about $91,218 dollars, this
leaves $66,588.60 Out of this remaining money, other necessities
must be paid.61 Data exists regarding nearly all consumer expenditures. However, the expenditures
that “count” in this analysis must
be “necessary.”62 Necessary expenditures include childcare,
food, housing, taxes, transportation, and certain miscellaneous
expenses (calculated as 10% of
other costs).63 These expenses total $42,557 dollars.64 Combined
with health care costs of $24,630
dollars, this family of four will
pay $67,187 dollars to simply survive. The family will retain
$24,031 dollars, or 25.5%, of their
annual income to be used for “non
-essentials.”65 Of the $67,187 dollars of necessary expenses, 35.8%
derive from health care and
18.6% from OOP costs.66 All of
these costs must be taken into account because they are necessities. Housing and food must be
considered in any discussion of
affordability. These necessities
are not itemized by the family,

and so neither should they be
itemized in any discussion of the
goals of a law directed towards
making life essentials affordable.
This one scenario illustrates clearly where the PPACA
fails to deliver: to those most at
risk and most vulnerable. A significant portion of families filing
for bankruptcy do so because of
medical reasons.67 This is the
class that the PPACA purports to
protect the most. Instead, the
PPACA envisions a system of
health insurance that assumes
good health, and leaves those
with the most serious health
problems out to dry. Much federal legislation has been designed
to provide a social safety net.68
The PPACA, however, is designed less as a safety net and
more as simple insurance regulation to prevent price gouging.69
However, if, as Title I of
PPACA claims, the Act envisions “affordable health care for
all Americans” then medical
bankruptcy should cease to exist
following the implementation of
all PPACA provisions.70 As
demonstrated above, unfortunately families outside the structure of price modifications shall
continue to suffer.71
Thus, there is the gaping
hole in the PPACA. A typical
family of four making an average income must pay a quarter of
their income towards health care
Continued on page 34
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should one member get severely
ill.72 When taking other necessary expenses into account, as
the literature suggests must be
done to truly measure affordability, the family retains merely
one quarter of their annual income. To pose a purely economic argument, with such little disposable income their contribution to consumption in areas other than health care diminishes
greatly and therefore harms all
other sectors of the economy.73
Even if this family remains perfectly healthy (and so must only
pay a premium for the health
insurance) their premium exceeds virtually all determinations of affordability.74
The true problem with
the gap in affordability, especially with the nature of the gap being predominately an extreme
exposure to out of pocket costs,
lies with medical bankruptcy as
discussed above. A study conducted and published in the
American Journal of Medicine
analyzed the effect that the Massachusetts health care reform
laws, enacted between 2006 and
2007, had on medical bankruptcy in the state.75 The study was
performed in order to shed light
on how national health reform,
in the form of the PPACA,
would affect nationwide medical
bankruptcy. The analogy is possible because the PPACA closely resembles the Massachusetts
reforms and in many ways the
Massachusetts reforms were a

precursor to the PPACA.76 The
study concluded that, while the
number of uninsured decreased,
the Massachusetts health reform
laws did not decrease the amount
of medical bankruptcies.77 The
study further concluded that the
Massachusetts reforms left many
of the insured with inadequate
financial protection.78
THE PATIENT PROTECTION AND
AFFORDABLE CARE ACT SUPPOSEDLY PROVIDES AFFORDABLE
HEALTH CARE TO ALL AMERICANS. FOR MUCH OF THE CITIZENRY OF THE UNITED STATES,
THE SYSTEM CREATED BY THE
PPACA WILL LIKELY HELP ALLEVIATE SOME OF THE BURDENS OF
ACQUIRING HEALTH INSURANCE…UNFORTUNATELY, THERE
ARE SIGNIFICANT HOLES IN THE
RELATIVELY NEW LAW.

This risk of medical bankruptcy may affect even those individuals and families able to scrape
by while incurring heavy medical
costs. By investing so much income into health care, the family
loses its capability of absorbing
any shock to either their expenditures or their income. If suddenly
one of the two working heads of
the household loses their job, the
ability to sustain high medical
costs may, with little warning, put
that family on the path to medical
bankruptcy. In the same vein, a
sudden sharp expenditure, such as
the need to purchase a new car
due to an accident, may also put a

family with no anti-shock capability over the edge. In either case
the PPACA places families in a
situation with no anti-shock ability and thus one bad life event
away from possible medical
bankruptcy.
Combining the gap in the
PPACA’s cost sharing provisions
and the study above, the
PPACA’s potential failure to protect those most vulnerable to financial disaster due to medical
costs jumps out. Medical bankruptcy will still be a very real
possibility for those in the gap,
such as the family of four making
403% of the poverty level described above. Couple these currently existing gaps in affordability with the rate of medical cost
inflation and the PPACA allows,
albeit unintentionally, families
that endure high medical costs to
experience the kind of economic
pressure that the PPACA should
be eliminating.
Conclusion
The Patient Protection and
Affordable Care Act supposedly
provides affordable health care to
all Americans. For much of the
citizenry of the United States, the
system created by the PPACA
will likely help alleviate some of
the burdens of acquiring health
insurance and provide those left
out of the traditional employerprovided health insurance model
with access to health insurance at
a reasonable price and thus allow
them to receive health care affordably.
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Unfortunately, there are
significant holes in the relatively
new law. Generally, the Patient
Protection and Affordable Health
Care Act places a significantly
larger burden on families making
between 400% and 500% of the
federal poverty level (squarely
middle class income levels). Far
more serious, however, remains
the narrow case of a family of
modest income who unfortunately
experience serious medical costs
resulting in the maximum amount
of health care expenses the
PPACA allows the consumer to
bare. Here, the PPACA fails to
alleviate one of the largest causes
of bankruptcy in the United States.
This article is not a total
condemnation. Rather, the PPACA
simply contains some holes that
(much like the infamous Medicare
doughnut hole) leave a few vulnerable people out to dry. If the goal
of the PPACA and the Federal
Government is to ensure all citizens equal and affordable health
care coverage, then this problem
must be addressed and fixed.
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